非小细胞肺癌患者因姑息与非姑息适应症接受基线皮质类固醇的免疫检查点抑制剂结局
该研究纳入650例接受免疫检查点抑制剂治疗的非小细胞肺癌患者,比较基线泼尼松≥10 mg与0至<10 mg者的结局。≥10 mg组中位无进展生存期(mPFS)和中位总生存期(mOS)均更短。按适应症分析,仅因姑息适应症接受≥10 mg泼尼松者mPFS和mOS显著缩短,而因非癌症相关适应症接受≥10 mg者与0至<10 mg组无显著差异。
要点
- 基线泼尼松≥10 mg组mPFS 2.0个月 vs 0至<10 mg组3.4个月(P=0.01)。
- 基线泼尼松≥10 mg组mOS 4.9个月 vs 0至<10 mg组11.2个月(P<0.001)。
- 仅姑息适应症用≥10 mg泼尼松者mPFS和mOS显著缩短,非癌症相关适应症者无显著差异。
核心结论
- 基线接受≥10 mg泼尼松的NSCLC免疫治疗患者结局更差,但差异似乎由因姑息适应症接受皮质类固醇的预后不良亚组驱动。
研究设计与样本
- 研究比较了接受免疫检查点抑制剂治疗的非小细胞肺癌患者中,基线泼尼松≥10 mg者与0至<10 mg者的临床结局。
主要发现
- 650例患者中93例(14.3%)在免疫治疗开始时接受≥10 mg泼尼松。
- ≥10 mg泼尼松组mPFS 2.0个月 vs 0至<10 mg组3.4个月(P=0.01)。
- ≥10 mg泼尼松组mOS 4.9个月 vs 0至<10 mg组11.2个月(P<0.001)。
- 按原因分析,姑息适应症组、非癌症相关原因组和0至<10 mg组的mPFS分别为1.4、4.6和3.4个月(三组log-rank P<0.001)。
- 三组mOS分别为2.2、10.7和11.2个月(三组log-rank P<0.001);非癌症相关原因组与0至<10 mg组mPFS和mOS无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Baseline use of corticosteroids is associated with poor outcomes in patients with non-small-cell lung cancer (NSCLC) treated with programmed cell death-1 axis inhibition. To approach the question of causation versus correlation for this association, we examined outcomes in patients treated with immunotherapy depending on whether corticosteroids were administered for cancer-related palliative reasons or cancer-unrelated indications. PATIENTS AND METHODS: Clinical outcomes in patients with NSCLC treated with immunotherapy who received ≥ 10 mg prednisone were compared with outcomes in patients who received 0 to < 10 mg of prednisone. RESULTS: Of 650 patients, the 93 patients (14.3%) who received ≥ 10 mg of prednisone at the time of immunotherapy initiation had shorter median progression-free survival (mPFS) and median overall survival (mOS) times than patients who received 0 to < 10 mg of prednisone (mPFS, 2.0 v 3.4 months, respectively; P = .01; mOS, 4.9 v 11.2 months, respectively; P < .001). When analyzed by reason for corticosteroid administration, mPFS and mOS were significantly shorter only among patients who received ≥ 10 mg prednisone for palliative indications compared with patients who received ≥ 10 mg prednisone for cancer-unrelated reasons and with patients receiving 0 to < 10 mg of prednisone (mPFS, 1.4 v 4.6 v 3.4 months, respectively; log-rank P < .001 across the three groups; mOS, 2.2 v 10.7 v 11.2 months, respectively; log-rank P < .001 across the three groups). There was no significant difference in mPFS or mOS in patients receiving ≥ 10 mg of prednisone for cancer-unrelated indications compared with patients receiving 0 to < 10 mg of prednisone. CONCLUSION: Although patients with NSCLC treated with ≥ 10 mg of prednisone at the time of immunotherapy initiation have worse outcomes than patients who received 0 to < 10 mg of prednisone, this difference seems to be driven by a poor-prognosis subgroup of patients who receive corticosteroids for palliative indications.
引用
- Ricciuti B, Dahlberg SE, Adeni A, et al. Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. J Clin Oncol. 2019. PMID: 31206316. doi:10.1200/JCO.19.00189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。